Juno Therapeutics Inc. (JUNO) 52.55 $JUNO
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 9:40AM CDT
Juno Therapeutics (JUNO) is expected to report fourth quarter 2014 results on Mar 18.
QURE: 24.88 (-0.37), CPRX: 4.37 (+0.19), JUNO: 52.55 (+3.06)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 34.42 (-0.03), HALO: 15.99 (+0.06), GILD: 100.99 (+1.38), JUNO: 52.55 (+3.06), ARNA: 4.77 (-0.04)
Juno Therapeutics to Report Full Year and Fourth Quarter 2014 Financial Results on Wednesday, March 18
GlobeNewswire - Wed Mar 11, 7:00AM CDT
Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2014 on Wednesday, March 18, 2015 after the close of U.S.-based financial markets. Hans E. Bishop, President and Chief Executive Officer, and Steven D. Harr, Chief Financial Officer, will host a conference call to review the results beginning at 2:00 p.m. Pacific Time (PT)/5:00 p.m. Eastern Time (ET).
JUNO: 52.55 (+3.06)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 123.37 (+3.44), ZIOP: 13.13 (-0.19), PFE: 34.41 (+0.41), XON: 45.63 (-0.86), AMGN: 161.64 (+7.38), GSK: 46.91 (+0.54), IMUC: 0.56 (-0.01), CELG: 120.33 (+2.60), JNJ: 100.71 (+1.50), BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83)
Analysis of the Global Oncology Drug Delivery Market 2015 - Future Impact of Emerging Technologies
M2 - Mon Mar 09, 11:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3fx4gm/analysis_of_the) has announced the addition of the "Analysis of the Global Oncology Drug Delivery Market " report to their offering. The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0% of the total global market in 2013 and will continue to grow stronger in 2015. Currently, the injectable drug delivery system segment leads the cancer drug delivery market; however, nanoparticles (including micro-needles, patches, and orals) are expected to lead the market in the future. Key Questions This Study Will Answer - Is the market growing? How long will it continue to grow, and at what rate? - Who are the key competitors in this market? - What are the major drivers and restraints in this market? - Which is the most attractive segment in the total oncology drug delivery market? - What are the upcoming technologies in the oncology drug delivery market? Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Competitive Playbook 4. Drivers and Restraints-Total Cancer Drug Delivery Market 5. Forecast and Trends-Total Cancer Drug Delivery Market 6. Injectable Drug Delivery System Segment Analysis 7. Oral Drug Delivery System Segment Analysis 8. Opportunities by Region 9. Opportunity by Technology 10. Key Companies to Watch 11. Conclusion 12. Appendix Companies Mentioned - Becton, Dickinson and Company (BD) - Evotec AG - Juno Therapeutics, Inc. - West Pharmaceuticals - NEONC Technologies Inc. (NTI) For more information visit http://www.researchandmarkets.com/research/3f...sis_of_the
JUNO: 52.55 (+3.06)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.16 (+0.11), GLMD: 9.08 (-0.18), PTBI: 3.40 (unch), CNAT: 5.65 (-0.07), GALT: 3.61 (+0.11), SRNE: 13.05 (-0.15), CELG: 120.33 (+2.60), GILD: 100.99 (+1.38), KITE: 63.45 (+0.36), CFRX: 5.40 (-0.40), ICPT: 297.95 (+16.57), JUNO: 52.55 (+3.06), CORT: 4.20 (+0.20)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 127.56 (+3.56), PCYC: 256.00 (+1.02), BMRN: 124.57 (+1.05), UTHR: 173.96 (+10.66), AMGN: 161.64 (+7.38), DYAX: 17.62 (+0.32), JNJ: 100.71 (+1.50), ESPR: 76.60 (+2.21), KITE: 63.45 (+0.36), RCPT: 148.28 (-1.14), PTCT: 73.47 (+0.20), ICPT: 297.95 (+16.57), ABBV: 58.80 (+0.80), JUNO: 52.55 (+3.06), SNY: 48.63 (+1.56)
Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST
KITE: 63.45 (+0.36), PPHM: 1.42 (+0.02), JUNO: 52.55 (+3.06)
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), PFE: 34.41 (+0.41), MRK: 57.04 (+0.84), JUNO: 52.55 (+3.06), BMY: 67.87 (+1.00), CBMG: 40.00 (+0.44), NVS: 97.87 (+0.83)
5 Stocks Ready for Breakouts: Juno Therapeutics, Cheetah Mobile and More
at The Street - Fri Feb 20, 6:00AM CST
These stocks look poised to break out and trade higher from current levels.
CMCM: 19.00 (+0.16), JUNO: 52.55 (+3.06), BAA: 0.17 (+0.01), OCLS: 0.82 (-0.04), ZAGG: 8.84 (-0.12)
Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 100.71 (+1.50), PCYC: 256.00 (+1.02), JPM: 61.71 (+0.71), GILD: 100.99 (+1.38), KITE: 63.45 (+0.36), ABBV: 58.80 (+0.80), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83), CELG: 120.33 (+2.60)
'Mad Money' Lightning Round: Just Say No to Conoco Stock
at The Street - Fri Feb 13, 5:00AM CST
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
FRPT: 17.75 (+0.75), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), CELG: 120.33 (+2.60), PEP: 95.27 (+0.95), DPS: 77.14 (+0.45), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), DATA: 93.75 (+1.09), REGN: 447.83 (+18.45)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 17.75 (+0.75), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), PEP: 95.27 (+0.95), CELG: 120.33 (+2.60), DPS: 77.14 (+0.45), ZTS: 46.77 (+0.32), HALO: 15.99 (+0.06), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), MRK: 57.04 (+0.84), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), REGN: 447.83 (+18.45)
Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest
at The Street - Thu Feb 12, 7:12PM CST
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
WFM: 54.55 (+0.34), MLM: 142.25 (+0.44),
69.94 (+0.98), TSLA: 194.00 (+5.32), FRPT: 17.75 (+0.75), SKX: 67.84 (-0.25), TRIP: 82.77 (+0.25), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), OWW: 11.73 (+0.02), PEP: 95.27 (+0.95), CELG: 120.33 (+2.60), WWAV: 41.80 (+0.04), DPS: 77.14 (+0.45), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), EXPE: 92.62 (+1.27), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), DATA: 93.75 (+1.09), AAPL: 124.15 (+0.56), REGN: 447.83 (+18.45), CSCO: 28.27 (+0.33)
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 7.36 (+0.17), OCAT: 6.38 (+0.19), VCEL: 3.75 (+0.06), PSTI: 2.93 (-0.03), NBS: 3.73 (-0.30), GSK: 46.91 (+0.54), IMUC: 0.56 (-0.01), KITE: 63.45 (+0.36), BAX: 68.23 (+0.87), ONCE: 66.35 (+0.57), JUNO: 52.55 (+3.06), ATHX: 2.94 (+0.12), CUR: 2.34 (-0.22)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 4.15 (-0.19), CLDX: 30.83 (+1.09), JUNO: 52.55 (+3.06), XOMA: 3.75 (+0.07), PDLI: 7.28 (unch)
Juno Therapeutics Establishes Manufacturing Presence in Washington State
GlobeNewswire - Mon Feb 09, 7:06AM CST
Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company's cell therapy products. The facility, which is expected to come online in early 2016, will support Juno's planned JCAR015 multicenter clinical trial, additional clinical programs in Juno's pipeline, and the company's first commercial products.
JUNO: 52.55 (+3.06)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 123.37 (+3.44), CLRB: 2.57 (-0.06), BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83)
Biotechs and Drugmakers Expected to Seek More Mergers in 2015
at The Street - Fri Feb 06, 12:23PM CST
The perceived risk from macroeconomic issues — such as those in Europe — as well as changes in both interest rates and oil prices will make outright sales more attractive.
RDUS: 48.35 (+0.99), JUNO: 52.55 (+3.06)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.67 (-0.38), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06)
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 9:40AM CDT
Juno Therapeutics (JUNO) is expected to report fourth quarter 2014 results on Mar 18.
QURE: 24.88 (-0.37), CPRX: 4.37 (+0.19), JUNO: 52.55 (+3.06)
Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 34.42 (-0.03), HALO: 15.99 (+0.06), GILD: 100.99 (+1.38), JUNO: 52.55 (+3.06), ARNA: 4.77 (-0.04)
Juno Therapeutics to Report Full Year and Fourth Quarter 2014 Financial Results on Wednesday, March 18
GlobeNewswire - Wed Mar 11, 7:00AM CDT
Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2014 on Wednesday, March 18, 2015 after the close of U.S.-based financial markets. Hans E. Bishop, President and Chief Executive Officer, and Steven D. Harr, Chief Financial Officer, will host a conference call to review the results beginning at 2:00 p.m. Pacific Time (PT)/5:00 p.m. Eastern Time (ET).
JUNO: 52.55 (+3.06)
Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 123.37 (+3.44), ZIOP: 13.13 (-0.19), PFE: 34.41 (+0.41), XON: 45.63 (-0.86), AMGN: 161.64 (+7.38), GSK: 46.91 (+0.54), IMUC: 0.56 (-0.01), CELG: 120.33 (+2.60), JNJ: 100.71 (+1.50), BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83)
Analysis of the Global Oncology Drug Delivery Market 2015 - Future Impact of Emerging Technologies
M2 - Mon Mar 09, 11:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3fx4gm/analysis_of_the) has announced the addition of the "Analysis of the Global Oncology Drug Delivery Market " report to their offering. The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0% of the total global market in 2013 and will continue to grow stronger in 2015. Currently, the injectable drug delivery system segment leads the cancer drug delivery market; however, nanoparticles (including micro-needles, patches, and orals) are expected to lead the market in the future. Key Questions This Study Will Answer - Is the market growing? How long will it continue to grow, and at what rate? - Who are the key competitors in this market? - What are the major drivers and restraints in this market? - Which is the most attractive segment in the total oncology drug delivery market? - What are the upcoming technologies in the oncology drug delivery market? Key Topics Covered: 1. Executive Summary 2. Market Overview 3. Competitive Playbook 4. Drivers and Restraints-Total Cancer Drug Delivery Market 5. Forecast and Trends-Total Cancer Drug Delivery Market 6. Injectable Drug Delivery System Segment Analysis 7. Oral Drug Delivery System Segment Analysis 8. Opportunities by Region 9. Opportunity by Technology 10. Key Companies to Watch 11. Conclusion 12. Appendix Companies Mentioned - Becton, Dickinson and Company (BD) - Evotec AG - Juno Therapeutics, Inc. - West Pharmaceuticals - NEONC Technologies Inc. (NTI) For more information visit http://www.researchandmarkets.com/research/3f...sis_of_the
JUNO: 52.55 (+3.06)
How Alan Leong Of BioWatch News Keeps Successful Biotech Investing Simple
Life Sciences Report - Seeking Alpha - Thu Mar 05, 4:53PM CST
Biotechnology can be daunting to comprehend, but understanding is critical to successful investment. BioWatch News Founder Alan Leong has a nose for growth names, and his goal is to make their technology platforms clear to investors who might not...
CTRV: 4.16 (+0.11), GLMD: 9.08 (-0.18), PTBI: 3.40 (unch), CNAT: 5.65 (-0.07), GALT: 3.61 (+0.11), SRNE: 13.05 (-0.15), CELG: 120.33 (+2.60), GILD: 100.99 (+1.38), KITE: 63.45 (+0.36), CFRX: 5.40 (-0.40), ICPT: 297.95 (+16.57), JUNO: 52.55 (+3.06), CORT: 4.20 (+0.20)
AbbVie's high-priced takeout of Pharmacyclics bodes well for other biotechs with high potential drugs
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 7:52AM CST
VRTX: 127.56 (+3.56), PCYC: 256.00 (+1.02), BMRN: 124.57 (+1.05), UTHR: 173.96 (+10.66), AMGN: 161.64 (+7.38), DYAX: 17.62 (+0.32), JNJ: 100.71 (+1.50), ESPR: 76.60 (+2.21), KITE: 63.45 (+0.36), RCPT: 148.28 (-1.14), PTCT: 73.47 (+0.20), ICPT: 297.95 (+16.57), ABBV: 58.80 (+0.80), JUNO: 52.55 (+3.06), SNY: 48.63 (+1.56)
Wall Street's Current Play: 'Immunotherapy Of Cancer'
Chris Lacoursiere - at Seeking Alpha - Thu Feb 26, 10:39AM CST
KITE: 63.45 (+0.36), PPHM: 1.42 (+0.02), JUNO: 52.55 (+3.06)
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital's Stephen Dunn
Life Sciences Report - Seeking Alpha - Fri Feb 20, 11:11AM CST
Immuno-oncology-disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in...
BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), PFE: 34.41 (+0.41), MRK: 57.04 (+0.84), JUNO: 52.55 (+3.06), BMY: 67.87 (+1.00), CBMG: 40.00 (+0.44), NVS: 97.87 (+0.83)
5 Stocks Ready for Breakouts: Juno Therapeutics, Cheetah Mobile and More
at The Street - Fri Feb 20, 6:00AM CST
These stocks look poised to break out and trade higher from current levels.
CMCM: 19.00 (+0.16), JUNO: 52.55 (+3.06), BAA: 0.17 (+0.01), OCLS: 0.82 (-0.04), ZAGG: 8.84 (-0.12)
Be Careful: These Biotechs Have Run Too Far Too Fast
Motley Fool Staff - Motley Fool - Mon Feb 16, 10:13AM CST
In biotechnology, stocks sometimes get a bit too far in front of themselves. When that happens, shares can take a big dip; so we asked three Motley Fool experts to weigh in on which stocks they think have climbed too much, too quickly. : On the...
JNJ: 100.71 (+1.50), PCYC: 256.00 (+1.02), JPM: 61.71 (+0.71), GILD: 100.99 (+1.38), KITE: 63.45 (+0.36), ABBV: 58.80 (+0.80), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83), CELG: 120.33 (+2.60)
'Mad Money' Lightning Round: Just Say No to Conoco Stock
at The Street - Fri Feb 13, 5:00AM CST
Cramer wants to own FreshPet and prefers Pepsico over Dr Pepper Snapple.
FRPT: 17.75 (+0.75), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), CELG: 120.33 (+2.60), PEP: 95.27 (+0.95), DPS: 77.14 (+0.45), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), DATA: 93.75 (+1.09), REGN: 447.83 (+18.45)
Disney Is A Long-Term Buy - Cramer's Lightning Round (2/12/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Fri Feb 13, 4:32AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, February 12. Bullish Calls: Xerox (NYSE: XRX ): "The last quarter was not good and the stock should have gone down," said Cramer. He thinks...
FRPT: 17.75 (+0.75), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), PEP: 95.27 (+0.95), CELG: 120.33 (+2.60), DPS: 77.14 (+0.45), ZTS: 46.77 (+0.32), HALO: 15.99 (+0.06), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), MRK: 57.04 (+0.84), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), REGN: 447.83 (+18.45)
Jim Cramer's 'Mad Money' Recap: Buy the Best and Leave the Rest
at The Street - Thu Feb 12, 7:12PM CST
Rarely does the market put the winning lottery ticket right in front of you, but today's winners were hiding in plain sight, Cramer says.
WFM: 54.55 (+0.34), MLM: 142.25 (+0.44),
69.94 (+0.98), TSLA: 194.00 (+5.32), FRPT: 17.75 (+0.75), SKX: 67.84 (-0.25), TRIP: 82.77 (+0.25), COP: 61.90 (+0.26), DIS: 107.45 (+1.01), XRX: 12.89 (+0.14), OWW: 11.73 (+0.02), PEP: 95.27 (+0.95), CELG: 120.33 (+2.60), WWAV: 41.80 (+0.04), DPS: 77.14 (+0.45), ISIS: 71.92 (+1.26), TSRA: 40.00 (+0.58), EXPE: 92.62 (+1.27), JUNO: 52.55 (+3.06), SPLK: 61.10 (-1.72), DATA: 93.75 (+1.09), AAPL: 124.15 (+0.56), REGN: 447.83 (+18.45), CSCO: 28.27 (+0.33) NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
CAPR: 7.36 (+0.17), OCAT: 6.38 (+0.19), VCEL: 3.75 (+0.06), PSTI: 2.93 (-0.03), NBS: 3.73 (-0.30), GSK: 46.91 (+0.54), IMUC: 0.56 (-0.01), KITE: 63.45 (+0.36), BAX: 68.23 (+0.87), ONCE: 66.35 (+0.57), JUNO: 52.55 (+3.06), ATHX: 2.94 (+0.12), CUR: 2.34 (-0.22)
Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 4.15 (-0.19), CLDX: 30.83 (+1.09), JUNO: 52.55 (+3.06), XOMA: 3.75 (+0.07), PDLI: 7.28 (unch)
Juno Therapeutics Establishes Manufacturing Presence in Washington State
GlobeNewswire - Mon Feb 09, 7:06AM CST
Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company's cell therapy products. The facility, which is expected to come online in early 2016, will support Juno's planned JCAR015 multicenter clinical trial, additional clinical programs in Juno's pipeline, and the company's first commercial products.
JUNO: 52.55 (+3.06)
Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 123.37 (+3.44), CLRB: 2.57 (-0.06), BLCM: 25.02 (+2.19), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06), NVS: 97.87 (+0.83)
Biotechs and Drugmakers Expected to Seek More Mergers in 2015
at The Street - Fri Feb 06, 12:23PM CST
The perceived risk from macroeconomic issues — such as those in Europe — as well as changes in both interest rates and oil prices will make outright sales more attractive.
RDUS: 48.35 (+0.99), JUNO: 52.55 (+3.06)
Northwest Has A Differentiated Technology Platform In The Emerging Immuno-Oncology Landscape
Smith On Stocks - Seeking Alpha - Fri Feb 06, 11:08AM CST
Investment Overview Linda Powers was invited to the 7th Annual Phacilitate Immunotherapy Forum in Washington D.C. to speak on the potential role of personalized immunotherapy drugs in the treatment of cancer. She was prominently featured in the ...
NWBO: 7.67 (-0.38), KITE: 63.45 (+0.36), JUNO: 52.55 (+3.06)
